Have a Claim?

Click here for a confidential contact or call:

1-212-350-2764

September 27, 2019

Posted  September 27, 2019

Pharmaceutical manufacturer Mylan N.V. has agreed to pay $30 million to resolve SEC charges that the company failed to disclose or adequately accrue for possible losses arising from a DOJ investigation into Mylan’s classification, pricing, and rebate practices regarding its EpiPen product.  In 2017, Mylan agreed to pay $465 million to resolve that DOJ investigation.  SEC

Tagged in: Accounting Fraud, Financial and Investment Fraud, Misrepresentations, Pharma Fraud, Securities Fraud,

Newsletter

Subscribe to receive email updates from the Constantine Cannon blogs

Sign up for: